https://www.selleckchem.com/products/gsk046.html
f perioperative complications but also experienced similar improvements in pain, function, and quality of life. A high rate of satisfaction was achieved. LEVEL OF EVIDENCE Level II, prognostic study.BACKGROUND In consideration of the difficulty in diagnosing high heterogeneous glioma, valuable prognostic markers are urgent to be investigated. This study aimed to verify that connective tissue growth factor (CTGF) is associated with the clinical prognosis of glioma, also to analyze the effect of CTGF on the biological function. METHODS In
Like
Comment
Share
